FIELD: medicine.
SUBSTANCE: invention relates to the field of clinical immunology, namely to the use of arabinogalactouronans of Saussurea salicifolia (L.) DC. as an agent for stimulating humoral and cellular Th1-type immune response, activation of production of Th1 specific cytokines of interleukin-12, tumour necrosis factor-alpha, interleukin-1 beta.
EFFECT: invention enables to expand the range of immunomodulatory agents of herbal origin, having the ability to selectively stimulate immunocompetent cells to produce pro-inflammatory cytokines interleukin-12, tumour necrosis factor-alpha, interleukin-1 beta and activate the humoral and cellular response of the immune system.
1 cl, 5 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT BASED ON WATER-SOLUBLE VEGETABLE POLYSACCHARIDES, HAVING ANTIALLERGIC ACTIVITY | 2023 |
|
RU2823873C1 |
AGENT HAVING IMMUNOMODULATORY ACTIVITY | 2018 |
|
RU2697526C1 |
IMMUNOMODULATING HUMIC AGENT | 2020 |
|
RU2756353C1 |
AGENT HAVING IMMUNOMODULATORY ACTIVITY | 2019 |
|
RU2734420C1 |
AGENT BASED ON WATER-SOLUBLE PLANT POLYSACCHARIDES, ENHANCING NITRIC OXIDE SECRETION BY MACROPHAGES IN VITRO | 2018 |
|
RU2735080C2 |
AGENT OF HUMIC NATURE OF IMMUNOMODULATING ACTIVITY | 2017 |
|
RU2662094C1 |
IMMUNOMODULATORY DRUG | 2011 |
|
RU2470656C1 |
HUMIC SUBSTANCE HAVING IMMUNOMODULATORY ACTIVITY | 2019 |
|
RU2716504C1 |
MEANS OF IMMUNOMODULATING ACTIVITY | 2017 |
|
RU2657819C1 |
IMMUNOMODULATORY DRUG | 2010 |
|
RU2421232C1 |
Authors
Dates
2025-03-14—Published
2024-04-16—Filed